^
    Back
    Association details:
    Biomarker:ALK-LIMS1 fusion
    Cancer:Lung Adenocarcinoma
    Drug:Xalkori (crizotinib) (ALK inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C4 – Case Studies
    Source:
    Onco Targets Ther
    Title:

    Ineffectiveness of Crizotinib in a Non-Small-Cell Lung Cancer with Novel ALK- LIMS1 Fusion: A Case Report

    Published date:
    02/17/2023
    Excerpt:
    We reported on a 48-year-old male Chinese patient with advanced lung adenocarcinoma harboring a novel ALK-LIMS1 who showed no response to crizotinib.
    DOI:
    https://doi.org/10.2147/OTT.S388962